Sugi Predict

Sugi Predict / Compounds / SCHEMBL390389

SCHEMBL390389

SCHEMBL390389

COC(=O)CC(NC(=O)OC(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1B Q00975 1/20 0.45
▸ PPARG P37231 1/20 0.44
▸ PPARA Q07869 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ TRPA1 O75762 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ CYP26A1 O43174 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ P2RY2 P41231 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ LMNA P02545 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ S1PR3 Q99500 1/20 0.40
▸ TP53 P04637 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ AGTR1 P30556 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392792 1.00 CACNA1B (0.45) CACNA1BPPARGPPARAALDH1A1MAPT
SCHEMBL390390 1.00 CACNA1B (0.45) CACNA1BPPARGPPARAALDH1A1MAPT
SCHEMBL391918 0.88 KMT2A (0.53) CACNA1BPPARGPPARAALDH1A1MAPT
SCHEMBL7334591 0.88 CTSS (0.44) CACNA1BPPARAALDH1A1MAPTKMT2A
SCHEMBL5221967 0.88 MEN1 (0.41) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL24440386 0.88 PPARG (0.43) PPARGPPARAALDH1A1MAPTCYP26A1
SCHEMBL24440108 0.88 MEN1 (0.41) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL391917 0.88 KMT2A (0.53) CACNA1BPPARGPPARAALDH1A1MAPT
SCHEMBL13118106 0.88 CTSS (0.44) CACNA1BPPARAALDH1A1MAPTKMT2A
SCHEMBL390624 0.88 KMT2A (0.53) CACNA1BPPARGPPARAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 — — US disclosed
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 — — US disclosed
US-10059714-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2018-08-28 — — US disclosed
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2017-03-02 — — US disclosed
EP-2201012-B1 PYRROLO[2,3-D]PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2014-06-25 — — EP disclosed
CN-101861321-B Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2013-02-06 — — CN disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
CN-101861321-A Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2010-10-13 — — CN disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
US-7041667-B1 CCR5 modulators PFIZER, INC. (US) 2006-05-09 — — US disclosed
EP-1013276-A1 Aminoazacycloalkanes as CCR5 modulators PFIZER INC. (US) 2000-06-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-10059714-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CACNA1B 2767/4885PPARG 3172/4885PPARA 3942/4885
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CACNA1B 2767/4885PPARG 3172/4885PPARA 3942/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CACNA1B 2767/4885PPARG 3172/4885PPARA 3942/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CACNA1B 3023/4885PPARG 3405/4885PPARA 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.